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Minor (5–10 fold) activation of mitogenic signalling cascades typically induces cell division upon
extracellular stimulation and is sufﬁcient to support tumourigenesis when permanently triggered
by activating mutations. Surprisingly, even strong signalling protein overexpression usually does
not trigger deregulated cell proliferation, suggesting that basal state signalling is insensitive to wild-
type protein overexpression. Using kinetic modelling of the core Ras cycle, we show that basal Ras-
GTP signalling can be insensitive to Ras overexpression and thus identify a possible tumour
suppression mechanism. We further show how phenotypically silent overexpression events within
signalling cascades cooperate to bring about carcinogenesis. Our analyses underscore the need for a
systems level understanding of tumour formation.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction endogenous promoter develop tumours [4]. (iii) Overexpression ofNormal cells require extracellular mitogenic signals to pass
from quiescence into a proliferative state. Cancer cells escape the
requirement for extracellular stimulation by constitutive activa-
tion of intracellular mitogenic signalling pathways [1].
The small GTPase Ras transduces signals from extracellular
growth factors, and controls various cellular responses including
proliferation. The Ras protein binds to guanine nucleotides, and cy-
cles between inactive and active states by switching between GDP-
and GTP-bound forms. Guanine nucleotides bound to Ras are ex-
changed even in the absence of other proteins by slow associa-
tion-dissociation reactions, and Ras-bound GTP is hydrolyzed to
GDP by the weak intrinsic GTPase activity of Ras. Within the cell,
these reactions are strongly enhanced by guanine nucleotide ex-
change factors (GEFs) and GTPase-activating proteins (GAPs),
respectively (Fig. 1A). Growth factors trigger the accumulation of
active GTP-bound Ras by enhancing GEF activity and/or by inhibit-
ing GAPs [2].
Aberrant RasGTP signalling is a common feature of tumours, as
30% of all tumours are characterized by Rasmutationswhich impair
GTPase activity, and thus lock Ras in the active GTP-bound state [2].
A relatively low intracellular RasGTP concentration already seems
sufﬁcient to promote normal cell proliferation or tumourigenesis:
(i) Even saturating growth factor concentrations typically induce
no more than 5–10 fold Ras activation (e.g., [3]). (ii) Heterozygous
knock-in mice expressing mutant Ras under the control of thechemical Societies. Published by E
. Legewie).GEFs [5,6] or downregulation of GAPs [7] induces a tumour-like
phenotype (i.e., transformation) in cell culture. However, the Ras-
GTP concentration is only increased by 3–10 fold in these cells.
Assuming that the basal RasGTP concentration is proportional to
the absolute Ras expression level, one expects that even relatively
minor (5–10 fold) overexpression of wildtype Ras should be sufﬁ-
cient to induce tumourigenesis. Indeed, it is known that overex-
pressed wildtype Ras can, in principle, cause the same tumours as
its mutant counterparts [8]. However, in most experimental set-
tings even strong overexpression of wildtype Ras induces at best
weak cellular transformation (e.g., [6,9]). Biochemical analyses sug-
gest that the inability of wildtype Ras to transformmost cell types is
due to an overexpression insensitivity mechanism emerging in the
Ras signalling network. More speciﬁcally, the fractional activation
of Ras (i.e., the amount of RasGTP divided by the total Ras concen-
tration) in the basal state decreases with increasing Ras expression
in several cell lines [7,10]. Accordingly, it was shown that Ras over-
expression alone does not enhance downstream signalling in the
unstimulated basal state [9,11]. It was the aim of this study to iden-
tify the requirements and the molecular mechanisms underlying
such overexpression insensitivity.2. Results and discussion
2.1. Overexpression insensitivity of basal Ras signalling
The core Ras cycle (Fig. 1A) comprising the intrinsic and
GAP-catalyzed GTPase reactions, as well as spontaneous andlsevier B.V. All rights reserved.
Fig. 1. Modelling Ras signalling. (A) Schematic representation of the model. GEF- and GAP-catalyzed reactions were modelled with Michaelis–Menten kinetics, and the
intrinsic steps with ﬁrst-order kinetics (GTP and GDP are assumed to be present in excess). See Supplementary section 1 for details. (B) Effects of Ras overexpression on signal
transduction. The steady state RasGTP concentration is plotted as a function of total Ras expression (i.e., the sum of RasGTP, RasGDP and Ras). A simple linear relationship is
observed if only the ﬁrst-order intrinsic reaction steps (grey arrows in A) are taken into account (grey line), while overexpression insensitivity arises if only the GEF- and GAP-
catalyzed reactions are considered (black arrows in A; black lines). The default kinetic parameters and the intracellular Ras expression level (indicated by vertical dashed line)
were taken from Stites et al. [12]. The KM-value for the GEF-catalyzed reaction (i.e., RasGDP? RasGTP) was varied as indicated by the arrow (line 1: KM,GEF = 3.86  106 mol/
l; line 2: KM,GEF = 3.86  105 mol/l; line 3: KM,GEF = 3.86  104 mol/l; line 4: KM,GEF = 3.86  103 mol/l).
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and the model predictions were validated experimentally [12,13].
In this paper, a slightly simpliﬁed version of the Stites model is
analyzed (Supplementary section 1 and Fig. 1A), with a special fo-
cus on how Ras overexpression affects basal state signal transduc-
tion in unstimulated cells. The simulated RasGTP level is analyzed
as the physiologically relevant output since the degree of DNA syn-
thesis and of cellular transformation are known to be titrable func-
tions of the intracellular RasGTP concentration [14].
The mechanism of basal Ras cycling in the unstimulated state is
known to be dependent on the cellular context. In some cell types,
intrinsic GTPase and exchange reactions predominate over the
GEF- and GAP-catalyzed steps [3]. In most cell types, however, ba-
sal Ras cycling in starvation media was shown to be dominated by
the GEF- and GAP-catalyzed reactions (e.g., [15–17]). We therefore
analyzed two extreme case models: an ‘‘intrinsic model” compris-
ing only the grey reaction steps in Fig. 1A and a ‘‘GEF–GAP model”
consisting of the black arrows in Fig. 1A. In the latter case, basal
state signalling was modelled by assuming that the maximal veloc-
ity for the GAP-catalyzed reaction strongly exceeds that of the GEF-
catalyzed reaction.
In Fig. 1B, the basal steady state RasGTP level was simulated as
a function of the total Ras concentration in order to investigate
how Ras overexpression affects Ras signalling in the model. The
intrinsic model showed a simple linear relationship between the
amounts of GTP-bound and total Ras (Fig. 1B, grey line). Such di-
rect proportionality might be expected because the intrinsic
GTPase and exchange reactions occur with ﬁrst-order kinetics
(note that GTP and GDP are assumed to be in excess). In contrast,
for the GEF–GAP model, the basal RasGTP level no longer increases
with increasing Ras expression, once the intracellular Ras expres-
sion is sufﬁciently high. Thus, nonlinearities (i.e., Michaelis–
Menten kinetics) in the GEF- and GAP-catalyzed reactions can
explain the overexpression insensitivity which was observed
experimentally (see Section 1). From a mechanistic point of view,
overexpression insensitivity arises because the concentration of
RasGDP signiﬁcantly exceeds that of RasGTP in the basal state.
Thus, the GEF-catalyzed reaction tends to be more saturated thanthe GAP-catalyzed reaction, so that increased GEF catalysis due
increasing Ras expression will be outbalanced by a stronger rela-
tive increase in GAP catalysis provided that Ras expression is suf-
ﬁciently high.
For the default kinetic parameter set proposed in Stites et al.
(corresponding simulations are marked with ‘‘default” in Fig. 1B),
overexpression insensitivity is restricted to high intracellular Ras
expression levels (lM range) which are observed in certain cell
types only [18]. Most cells quantitatively characterized to date ex-
hibit lower Ras concentrations (a typical value is indicated by the
vertical dashed line in Fig. 1B), and thus do not show overexpres-
sion insensitivity when simulated using the default Stites parame-
ters. In the following, we will derive analytical expressions for Ras
basal state signalling and will show that overexpression insensitiv-
ity is also expected for a ‘‘typical” cell (expressing sub-micromolar
levels of Ras) provided that more physiological enzymatic param-
eters are assumed for the GEF reaction.
An analytical expression was derived for the steady state of the
GEF–GAP model. As a measure for the overexpression insensitivity
range we analyzed the half-saturation Ras expression level (Ras-
tot,50), where RasGTP reaches half of its maximal value. This quan-
tity, which corresponds to the KM-value of a Michaelis–Menten
equation, is given by:
Rastot;50 ¼ 12 
KM;GAP þ 2  Vmax;GAP=Vmax;GEF  KM;GEF
Vmax;GAP=Vmax;GEF  1 ð1Þ
The maximal velocity Vmax equals the catalytic rate constant
(kcat) multiplied by the total enzyme concentration. Assuming
weak basal state signalling (Vmax,GAP Vmax,GEF) and considering
that the Michaelis–Menten constant of the GAP-catalyzed reaction
(KM,GAP) is typically lower than that of the GEF-catalyzed reaction
(KM,GEF), this simpliﬁes to:
Rastot;50  KM;GEF ð2Þ
Thus, overexpression insensitivity will be observed if the total
intracellular Ras concentration exceeds the Michaelis–Menten
constant of the GEF-catalyzed reaction as also shown by the black
lines in Fig. 1B.
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insensitivity, we compared the default KM,GEF assumed in the Stites
model with published kinetic measurements. Two lines of evi-
dence suggest that the typical KM,GEF within living cells is two or
more orders of magnitude lower than that in the default Stites
model. First, it is known that Ras is subject to post-translational
farnesylation in living cells and that such processing drastically en-
hances the Ras–GEF interaction [19], an effect that is not taken into
account in the Stites model. Second, several Ras–GEFs including
Sos, the major intracellular GEF, are characterized by Michaelis–
Menten constants much lower than that assumed in the Stites
model (see Supplementary section 3). Thus, the effective intracel-
lular KM,GEF will often be close to or even below the Ras concentra-
tion even in a ‘‘typical” cell expressing sub-micromolar levels of
Ras. According to Eq. (2), this further corroborates the physiologi-
cal relevance of the proposed overexpression insensitivity mecha-
nism. However, in certain cell types, overexpression insensitivity is
not observed and basal Ras signalling increases linearly with the
Ras expression level (e.g., [20]). Our analytical result (Eq. (2)) sug-
gests that the GEFs expressed in these cells are characterized by
KM-values that are large relative to the intracellular Ras
concentration.
2.2. Implications for oncogene cooperation
Tumourigenesis is a multistep process where genetic alterations
frequently cooperate to bring about much stronger transformation
than either event alone. In the following, we will analyze how indi-
vidual perturbations cooperate to enhance RasGTP signalling in the
GEF–GAP model.
Ras overexpression, though phenotypically silent, seems to
prime cells for a secondary activation event upstream of Ras as
schematically depicted in Fig. 2B (left branch). For instance, GEF
activators such as EGF induce much stronger MAPK activation in
cells overexpressing wildtype Ras when compared to control cells
[9,11]. Moreover, cellular transformation by transfection with con-Fig. 2. Implications for oncogene cooperation. (A) Effects of Ras overexpression on signal
that takes Ras sequestration in enzyme-substrate complexes into account. The GEF- and
irreversible Michaelis-Menten mechanism (E + SM ES? E + P; Supplementary section 2)
as a function of total Ras expression, and the total GEF concentration is varied. The total
[GEF]/[GAP] = 0.04, 0.4 and 4. Note that the curve for [GEF]/[GAP] = 4 represents the m
Schematic representation of the logical AND-gate for oncogene cooperation. Normal cells
B in panel A) or Ras overexpression (point C in panel A), while strong transformation is
panel A).stitutively active Sos GEF constructs (catalyzing RasGDP? Ras-
GTP) is much more efﬁcient if wildtype Ras is co-transfected
[5,6]. The GEF–GAP model is in accordance with such priming by
Ras overexpression as shown in Fig. 2A. More speciﬁcally, Ras over-
expression alone does not affect basal state signalling (point
A? point C in Fig. 2A). However, the fold change in RasGTP in-
duced by GEF activation is much greater in Ras overexpressing cells
(point C? point D in Fig. 2A) when compared to wildtype cells
(point A? point B in Fig. 2A). Thus, the simulation result is in
accordance with previous work by Goldbeter and Koshland [21]
who showed that the sensitivity in covalent modiﬁcation cycles in-
creases with increasing substrate expression (‘zero-order
ultrasensitivity’).
Interestingly, upstream GEF activation alone can also be insuf-
ﬁcient to induce cellular transformation unless Ras is additionally
overexpressed as schematically depicted in Fig. 2B (right branch).
Transfection with constitutively active GEF constructs does not
induce cellular transformation at least in some cell types, but
primes cells for strong transformation by transfection with wild-
type Ras [5,6,11]. The GEF–GAP model can explain such priming
(point A? point B in Fig. 2A) and subsequent transformation
(point B? point D in Fig. 2A) provided that the GEF and/or GAP
concentrations are comparable to that of Ras: Suppose that a
large pool of GAP molecules exists within the cell as indicated
by published quantitative experimental studies (see Supplemen-
tary section 2). Then, GAPs could efﬁciently bind to RasGTP and
thereby sequester Ras away from its downstream effectors, so
that signal transmission is suppressed even if GEFs are highly ac-
tive (point B in Fig. 2A). However, once the Ras concentration ex-
ceeds the GAP concentration, sequestration is suddenly relieved,
and Ras signalling rises steeply with increasing Ras expression
(point B? point D in Fig. 2A), an effect we have termed ultrasen-
sitization [22]. As summarized in Supplementary section 2, the
available literature is consistent with sequestration of Ras in en-
zyme-substrate complexes and thus supports the simulations
shown in Fig. 2A.transduction for varying upstream stimulus levels in the modiﬁed GEF–GAP model
GAP-catalyzed reactions are modelled using an elementary step description of the
, and the intrinsic reaction steps are neglected. The RasGTP concentration is plotted
GEF concentrations are 3  108, 3  107 and 3  106 mol/l which corresponds to
aximal effect induced by strong stimulation. Points A–D are described in B. (B)
(point A in panel A) can remain completely untransformed by GEF activation (point
observed if Ras overexpression and GEF activation occur simultaneously (point D in
96 S. Legewie et al. / FEBS Letters 583 (2009) 93–96In conclusion, the simulations shown in Fig. 2A demonstrate
that ultrasensitization and zero-order ultrasensitivity explain
why GEF activation and Ras overexpression can strongly cooperate
for tumourigenesis [5,6]. The behaviour schematically shown in
Fig. 2B is similar to a logical AND-gate known in engineering sci-
ences: Neither Ras overexpression nor GEF activation alone trans-
forms cells, while strong transformation is observed if Ras
overexpression and GEF activation occur simultaneously.
3. Concluding remarks
Oncogenes such as Ras are frequently overexpressed in tu-
mours, e.g., due to genomic ampliﬁcation or due to promoter
deregulation [23]. However, in many cases, the relevance of such
overexpression remains unclear and even strong overexpression
of wildtype proteins is insufﬁcient for cellular transformation
(see Supplementary section 4). The topology of the kinetic model
analyzed in this paper applies to signalling via (de)phosphorylation
cycles, so that the proposed mechanisms for tumour suppression
and oncogene cooperation are likely to be relevant for protein ki-
nase cascades as well. For instance, it seems that Ras and Raf coop-
erate in a logical AND-gate similar to that discussed in the context
of Fig. 2, as transfection with either wildtype protein did not in-
duce any signiﬁcant phenotypic response, while strong transfor-
mation was observed upon co-transfection of Ras and Raf [24].
Interestingly, the overexpression insensitivity mechanism pre-
sented here is related to that discussed for bacterial two-compo-
nent systems [25,26]. However, bacterial signalling cascades are
topologically distinct from mammalian systems, and accordingly
do not exhibit priming and cooperation effects such as those dis-
cussed in Fig. 2 [26]. Alternative (not mutually exclusive) overex-
pression insensitivity mechanisms are conceivable for Ras
signalling. For example, it is known that post-translational pro-
cessing steps such as farnesylation are necessary for the biological
activity of Ras [27]. Saturation of the enzymes involved in such
processing could explain why Ras overexpression fails to increase
basal signalling. Currently available experimental evidence, how-
ever, argues against saturation effects in Ras processing (see Sup-
plementary section 5 for further discussion), thus suggesting that
the overexpression insensitivity mechanism discussed in this pa-
per dominates under physiological conditions. The tumour sup-
pression and cooperation mechanisms proposed here can be
veriﬁed experimentally by mixing varying amounts of recombi-
nant Ras, GAP and GEF proteins in vitro, and by subsequently mea-
suring the steady state concentration of RasGTP as a readout. The
simulation results presented here, together with previous systems
biological analyses [12,28], underscore the need for a systems level
understanding of carcinogenesis.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2008.11.027.
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